Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
11 March 2021 - 9:27AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
the acceptance of five abstracts for poster presentation at the
upcoming American Association for Cancer Research (AACR) Annual
Meeting 2021 taking place virtually from April 10 – 15, 2021.
The poster presentations will be available on Saturday, April 10
at 8:30 am ET on the conference website as well as the Zymeworks
website.
Presentation Details
Title: PROTECT™, a novel antibody platform
for integrating tumor-specific immune modulation and enhancing the
therapeutic window of targeted multispecific biologics Abstract:
924 Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Title: Increasing the therapeutic index of
IL-12 by engineering for tumor-specific protease activation
Abstract: 1788 Session Category: Immunology Session Title:
Modifiers of the Tumor Microenvironment
Title: Understanding the geometry and valency
of bispecific antibodies in the optimization of tumor-dependent
activation of 4-1BB Abstract: 1737 Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions
Title: Super-resolution imaging studies of
zanidatamab: providing insights into its bispecific mode of action
Abstract: 1032 Session Category: Experimental and Molecular
Therapeutics Session Title: Cellular Responses to Anticancer
Drugs
Title: The bispecific antibody zanidatamab’s
(ZW25’s) unique mechanisms of action and durable anti-tumor
activity in HER2-expressing cancers Abstract: 1005 Session
Category: Experimental and Molecular Therapeutics Session Title:
Cellular Responses to Anticancer Drugs
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, zanidatamab (ZW25), is a novel Azymetric™
bispecific antibody which has been granted Breakthrough Therapy
designation by the FDA and is currently enrolling in a pivotal
clinical trial for refractory HER2-amplified biliary tract cancer
(HERIZON-BTC-01) as well as several Phase 2 clinical trials for
HER2-expressing gastroesophageal and breast cancers. Zymeworks’
second clinical candidate, ZW49, is a novel bispecific
HER2-targeting antibody-drug conjugate currently in Phase 1
clinical development and combines the unique design and antibody
framework of zanidatamab with Zymeworks’ proprietary ZymeLink™
linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this news release
include, but are not limited to, statements that relate to
Zymeworks’ clinical and preclinical development of its product
candidates, related clinical trials, and other information that is
not historical information. When used herein, words such as “will”,
“may”, and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Zymeworks may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various factors, including, without limitation, market
conditions and the factors described under “Risk Factors” in
Zymeworks’ Annual Report on Form 10-K for its fiscal year ended
December 31, 2020 (a copy of which may be obtained at www.sec.gov
and www.sedar.com). Consequently, forward-looking statements should
be regarded solely as Zymeworks’ current plans, estimates and
beliefs. Investors should not place undue reliance on
forward-looking statements. Zymeworks cannot guarantee future
results, events, levels of activity, performance or achievements.
Zymeworks does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210310005992/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Mary Klem (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2024 to May 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From May 2023 to May 2024